A Phase I, Open-Label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of BLYG8824A Administered Intravenously In Patients With Locally Advanced Or Metastatic Colorectal Cancer
This study will evaluate the safety, tolerability, and pharmacokinetics of BLYG8824A and will make a preliminary assessment of the anti-tumor activity of BLYG8824A in patients with locally advanced or metastatic colorectal cancer.
100 Clinical Results associated with CD3ε x LY6G6D
100 Translational Medicine associated with CD3ε x LY6G6D
0 Patents (Medical) associated with CD3ε x LY6G6D